MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Total Debt
Short-term and long-term borrowings combined.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 12.6% from a year ago
Total debt stood at $5.59M at the end of Q1 FY2026, down 12.6% from a year earlier and down 3.6% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.
Context
- Total debt amounted to 1.3% of total assets at the end of Q1 FY2026, down 4.4 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -12.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 5.8M USD
- Year-over-year change
- -11.8%
- 3-year CAGR
- -2.6%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.8M | -11.8% |
| FY2024 | 2024-12-31 | 6.58M | +11.1% |
| FY2023 | 2023-12-31 | 5.92M | -5.5% |
| FY2022 | 2022-12-31 | 6.27M | — |
Total Debt vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 total debt of $5.59M is the 5th highest of the 11 companies compared; the peer median is $2.46M.
- Its year-over-year change of -12.6% is the 4th highest of 9, against a peer median of -45.3%.
- Total debt amounts to 1.3% of total assets for MPLT, versus a peer median of 0.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $71.74M | — | — | 0.1% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $36.66M | -9.2% | — | 3.4% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $10.8M | +37.8% | +3.2% | 2.2% |
| Mar 2026 | $5.69M | -78.5% | -62.3% | 2.1% | |
| Mar 2026 | $5.59M | -12.6% | -2.6% | 1.3% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $3.47M | -7.7% | -47.1% | 0.9% |
| Mar 2026 | $1.46M | -89.9% | -6.7% | 0.6% | |
| Mar 2026 | $1.15M | -98.1% | +49.9% | 0.4% | |
| Mar 2026 | $432K | -34.3% | — | 0.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $410K | -56.3% | -61.6% | 0.3% |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding MPLT) | $2.46M | -45.3% | -26.9% | 0.5% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.